ResMed Inc. Form 10-Q Summary
Period: Fiscal third quarter and nine months ended March 31, 2022; filed April 28, 2022. The request metadata says “2021 Q3,” but the filing itself reports fiscal Q3 2022.
Business context and results
ResMed develops and sells sleep and respiratory care devices and operates software-as-a-service (SaaS) platforms for out-of-hospital care. Results reflect recovering sleep-care demand and increased device demand following a competitor’s product recall, alongside pandemic-related supply constraints.
| Metric | Three months ended March 31, 2022 | Year-over-year change | Nine months ended March 31, 2022 | Year-over-year change |
|---|---|---|---|---|
| Revenue | $864.5 million | +12% (+14% constant currency) | $2,663.4 million | +15% |
| Gross profit | $491.2 million | +10% | $1,501.8 million | +11% |
| Gross margin | 56.8% | Down from 58.2% | 56.4% | Down from 58.1% |
| Operating income | $234.3 million | Up from $223.4 million | $744.9 million | Up from $662.0 million |
| Net income | $179.0 million | Compared with a $78.5 million loss | $584.4 million | Up from $279.4 million |
| Diluted EPS | $1.22 | Compared with a $0.54 loss | $3.97 | Up from $1.91 |
| Operating cash flow | Not separately reported for the quarter | $271.7 million | Down from $510.2 million |
Revenue, margins, and material changes
- Quarterly Sleep and Respiratory Care revenue was $763.4 million, up 13% reported and 15% at constant currency. Device sales rose 18% globally; masks and other revenue rose 7%.
- Quarterly SaaS revenue was $101.1 million, up 8%, supported by growth in HME and Home Health and Hospice and stabilizing patient flow.
- Higher logistics and manufacturing costs reduced gross margin; favorable product mix and average selling prices partly offset the pressure. Management said supply constraints prevented the company from meeting all available demand.
- Quarterly GAAP net income improved substantially versus the prior-year loss, but the comparison is affected by a $254.8 million disputed-tax-position reserve reflected in prior-year non-GAAP reconciliation. For the nine-month period, the ATO settlement also affected tax expense and cash payments. The filing reports a 20.9% quarterly effective tax rate for 2022 versus 136.0% in 2021.
- Non-GAAP diluted EPS was $1.32 for the quarter versus $1.30, and $4.30 for nine months versus $3.98. These company-defined measures exclude specified items and should be considered alongside GAAP results.
Cash, debt, and liquidity
- At March 31, 2022, cash and cash equivalents were $201.8 million, total assets $4.9 billion, and stockholders’ equity $3.3 billion. Cash was down from $295.3 million at June 30, 2021.
- Nine-month operating cash flow was $271.7 million. The decrease from the prior year primarily reflected the $284.8 million final ATO settlement payment and higher inventory purchases and prepayments to secure components.
- Nine-month investing cash use was $174.7 million, including $106.2 million of property and equipment purchases. Financing cash use was $185.9 million, including $183.9 million of dividends paid.
- Reported debt, net of deferred borrowing costs, totaled $680.7 million. The filing also states $682.0 million of principal outstanding across credit facilities and senior notes. The $1.6 billion revolving facility was undrawn and available; management reported $1.8 billion of cash plus available revolver liquidity and expects liquidity to cover operations and anticipated capital expenditures for at least 12 months.
- Debt facilities mature April 17, 2023; senior notes of $250 million each mature in 2026 and 2029. The company said it was in compliance with debt covenants at March 31, 2022.
Outlook, risks, and unusual items
- No specific revenue or earnings guidance is provided in the supplied filing text. Management expected supply-chain constraints, especially semiconductor availability and freight capacity, to continue through the remainder of fiscal 2022, limiting the ability to meet demand and pressuring costs and margins.
- Management did not expect material incremental COVID-19-driven ventilator demand for the remainder of fiscal 2022. Core sleep-care pathways had largely recovered toward pre-pandemic levels in most markets.
- Purchase obligations were $1.57 billion, of which $1.47 billion was due by March 31, 2023. These commitments underscore procurement and supply-chain exposure.
- The ATO transfer-pricing dispute for tax years 2009–2018 was settled in September 2021, resolving prior years without admission of liability and providing clarity on certain future tax principles. The company remitted $284.8 million in final payment.
- Legal matters include a NYU patent-infringement case proceeding to discovery. An Ectosense trademark and advertising dispute was resolved by confidential settlement on April 5, 2022. ResMed said it could not reasonably estimate losses, if any, for remaining open matters and did not expect litigation outcomes, individually or collectively, to materially adversely affect the financial statements.
- The AirSense 11 launch continued during the quarter. The company reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.
Key facts for investors to verify
- Confirm the reporting period: this is the quarter ended March 31, 2022, not 2021 Q3.
- Track component availability, freight costs, purchase commitments, and whether ResMed can fulfill elevated demand following the competitor recall.
- Assess whether margin pressure eases; reported gross margin fell year over year despite revenue growth.
- Separate recurring earnings trends from the prior-year tax reserve and the ATO settlement’s tax and cash-flow effects.
- Review operating cash conversion, inventory growth to $664.9 million from $457.0 million at June 30, 2021, and upcoming April 2023 credit-facility maturity.
- Monitor developments in the NYU litigation and the company’s disclosed contingent exposures.